STERLING, Va., Nov. 30 /PRNewswire/ -- NanoMarkets has recently launched a new research project that addresses the role of nanotechnology in drug discovery and drug delivery. The findings will be released early in the first quarter of 2005. More information about the project can be viewed at http://www.nanomarkets.net. The cost and quality of healthcare will soon dominate virtually every fabric of society. Pharmaceutical and biotechnology companies are under immense pressures to produce a steady stream of affordable, yet innovative and well-differentiated drugs. However, to develop and market a drug, it currently takes an estimated seven to ten years at costs that exceed $800 million. And, every year approximately $65 billion in drug revenues are accounted for by pharmaceuticals with poor bio-availability which results in higher patient costs, inefficient treatment but, more importantly, increased risks of toxicity or even death. Nanotechnology has been discussed in several circles as a means to not only improve drug discovery and drug-delivery systems, but also as a means of creating new profitable products for pharmaceutical companies. About the Program: NanoMarkets' research is broken out into two parts. The first addresses the major drivers, restraints and challenges for current and emerging applications of nanotechnology in drug discovery. Areas covered include nano- enabled drug discovery technologies/tools, nano-enabled drugs and an assessment of key market engineering parameters. The technologies/tools covered include nanoarrays, nanomasspectrometry, nanolithography arrays, biological chips, congruent force intermolecular test, and solubility and reformulation methods. This report provides global market coverage and discusses funding, regulatory and ethical issues in the major industrial countries, with worldwide market forecasts over an eight-year forecast period. The second segment examines the business opportunities that are being created by nano-engineered solutions for the drug-delivery market. It examines which of the many emerging nano-enabled drug-delivery systems have the best prospects and when and where they are likely to be used. Areas covered include encapsulation technologies, implantable delivery methods, imaging agents and microneedles. Technologies covered include dendrimers, nanotubes and fullerenes, nanoparticles, quantum dots and magnetic/electrical targeting methods. The report also takes a look at the technical, market and regulatory barriers to implementing nano-enabled drug-delivery systems, and it notes likely differences in implementation patterns in the major industrialized countries. This report forecasts the market for new technologies broken out by drug-delivery type and technology platform. For Additional Information: NanoMarkets is making the reports available at a discounted rate through the end of 2004. For additional information about these reports, you may contact Robert Nolan at email@example.com or (571) 434-7520 or visit http://www.nanomarkets.net to learn more. About NanoMarkets: NanoMarkets analyzes the impact of nanotechnology on both established and emerging markets with a focus on the realms of communications, IT, semiconductors, bio-medical and energy. The firm provides market research reports, customized industry analyses and general market commentary for companies looking to capitalize on nanotechnology-based opportunities.